Acrivon Therapeutics (ACRV) said Wednesday the US Food and Drug Administration has granted its ACR-368 OncoSignature Assay Breakthrough Device designation.
The assay is designed to identify endometrial cancer patients who are likely to respond to the company's ACR-368 treatment, the company said. The designation accelerates the product's development, assessment, and review for approvals.
Shares of Acrivon Therapeutics were up nearly 21% in recent Wednesay trading.
Price: 7.15, Change: +1.24, Percent Change: +20.98
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。